Outcome of transcatheter atrial septal defect closure in a nationwide cohort.
Atrial septal defect
atrial fibrillation
complication
congenital heart disease
migraine
stroke
transcatheter closure
Journal
Annals of medicine
ISSN: 1365-2060
Titre abrégé: Ann Med
Pays: England
ID NLM: 8906388
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
entrez:
14
2
2023
pubmed:
15
2
2023
medline:
16
2
2023
Statut:
ppublish
Résumé
Transcatheter (TC) atrial septal defect (ASD) closure has been the mainstay of therapy for secundum-type ASDs for over 20 years. This nationwide cohort evaluated the long-term outcome of transcatheter-closed ASDs. The study enrolled every transcatheter ASD closure performed in Finland from 1999 to 2019. Five age, sex, and municipality-matched controls per ASD patient were gathered from the general population. The median follow-up period was 5.9 years (range 0-20.8). We used the hospital discharge register to gather all hospital visits and diagnoses. Closure complications and echocardiographic changes were collected from the electronic health records. Transcatheter ASD closure was performed in 1000 patients (68.5% females) during the study period. The median (range) age at the time of the procedure was 37.9 (1.8-87.5) years. ASD patients had an increased risk for new-onset atrial fibrillation (RR 2.45, 95% CI: 1.84-3.25), migraine (RR 3.61, 95% CI: 2.54-5.14), ischemic heart disease (RR 1.73, 95% CI: 1.23-2.45), ventricular fibrillation/tachycardia (RR 3.54 (95% CI: 1.48-8.43) and AV conduction disorder (RR 3.60, 95% CI: 1.94-6.70) compared to the control cohort. Stroke risk was not increased (RR 1.36, 95% CI: 0.91-2.03). Adverse events occurred in 6.3% ( After TC closure of ASD, patients had a higher risk of new-onset atrial fibrillation and migraine
Sections du résumé
BACKGROUND
Transcatheter (TC) atrial septal defect (ASD) closure has been the mainstay of therapy for secundum-type ASDs for over 20 years.
AIMS
This nationwide cohort evaluated the long-term outcome of transcatheter-closed ASDs.
METHODS
The study enrolled every transcatheter ASD closure performed in Finland from 1999 to 2019. Five age, sex, and municipality-matched controls per ASD patient were gathered from the general population. The median follow-up period was 5.9 years (range 0-20.8). We used the hospital discharge register to gather all hospital visits and diagnoses. Closure complications and echocardiographic changes were collected from the electronic health records.
RESULTS
Transcatheter ASD closure was performed in 1000 patients (68.5% females) during the study period. The median (range) age at the time of the procedure was 37.9 (1.8-87.5) years. ASD patients had an increased risk for new-onset atrial fibrillation (RR 2.45, 95% CI: 1.84-3.25), migraine (RR 3.61, 95% CI: 2.54-5.14), ischemic heart disease (RR 1.73, 95% CI: 1.23-2.45), ventricular fibrillation/tachycardia (RR 3.54 (95% CI: 1.48-8.43) and AV conduction disorder (RR 3.60, 95% CI: 1.94-6.70) compared to the control cohort. Stroke risk was not increased (RR 1.36, 95% CI: 0.91-2.03). Adverse events occurred in 6.3% (
CONCLUSION
After TC closure of ASD, patients had a higher risk of new-onset atrial fibrillation and migraine
Identifiants
pubmed: 36786506
doi: 10.1080/07853890.2023.2178669
pmc: PMC9930864
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
615-623Références
Can J Cardiol. 2016 Nov;32(11):1315.e11-1315.e18
pubmed: 27179546
Int Heart J. 2015;56(5):516-21
pubmed: 26370370
Am J Cardiol. 2009 May 15;103(10):1445-50
pubmed: 19427444
Heart. 2022 Jul 13;108(15):1216-1224
pubmed: 34675040
Open Heart. 2019 Jun 29;6(1):e001056
pubmed: 31328006
J Am Coll Cardiol. 2006 Mar 21;47(6):1226-7
pubmed: 16545656
Am Heart J. 2008 Oct;156(4):706-12
pubmed: 18926151
J Thorac Dis. 2018 Sep;10(Suppl 24):S2923-S2930
pubmed: 30305952
Catheter Cardiovasc Interv. 2015 Feb 1;85(2):227-33
pubmed: 25257700
Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1123-38
pubmed: 23412921
Heart. 2002 Nov;88(5):485-7
pubmed: 12381639
Int J Cardiol. 2013 Apr 5;164(2):217-20
pubmed: 21807422
Heart. 2015 May;101(9):706-11
pubmed: 25691512
J Thorac Cardiovasc Surg. 2009 Jun;137(6):1334-41
pubmed: 19464444
Heart Asia. 2016 Aug 01;8(2):26-31
pubmed: 27540418
Europace. 2017 Aug 01;19(8):1322-1326
pubmed: 27702856
Circ Cardiovasc Interv. 2020 Nov;13(11):e009841
pubmed: 33131301
JACC Cardiovasc Interv. 2015 Apr 20;8(4):600-6
pubmed: 25907086
Heart Lung Circ. 2008 Aug;17(4):318-24
pubmed: 18407789
J Am Coll Cardiol. 2002 Jun 5;39(11):1836-44
pubmed: 12039500
JACC Cardiovasc Interv. 2017 Nov 13;10(21):2211-2218
pubmed: 29055761
J Am Coll Cardiol. 2011 Nov 15;58(21):2241-7
pubmed: 22078432
J Cardiovasc Med (Hagerstown). 2017 Aug;18(8):605-609
pubmed: 28072626
Headache. 2012 Jun;52(6):985-92
pubmed: 22486257
JACC Cardiovasc Interv. 2021 Mar 8;14(5):566-575
pubmed: 33663785
Am J Cardiol. 2009 Feb 15;103(4):550-4
pubmed: 19195519
Heart. 2021 Dec;107(23):1875-1880
pubmed: 34380660
Cephalalgia. 2013 Nov;33(15):1229-37
pubmed: 23720500
Open Heart. 2020 Oct;7(2):
pubmed: 33020256
Sci Rep. 2019 May 15;9(1):7410
pubmed: 31092873
J Am Heart Assoc. 2023 Jan 17;12(2):e027635
pubmed: 36625312
Catheter Cardiovasc Interv. 2007 Oct 1;70(4):532-7
pubmed: 17896398
Front Neurol. 2017 Mar 20;8:68
pubmed: 28373854